Tenon Medical, Inc. (TNON) amended its ATM prospectus to permit it to offer and sell common stock with an aggregate offering price of up to $7,176,045 under its sales agreement with A.G.P./Alliance Global Partners, acting as sales agent or principal. This amount excludes $2,809,378 of common stock sold under the agreement during the 12 calendar months through October 16, 2026.
While public float remains below $75.0 million, Tenon's public primary offerings on Form S-3 are limited to one-third of public float in any 12 calendar month period. As of October 16, 2026, the aggregate market value of common stock held by non-affiliates was $29,956,270, calculated using 2,625,440 shares and a price of $11.41 per share, the August 19, 2026 closing price and highest closing sale price in the prior 60 days. If public float exceeds $75.0 million, the limit no longer applies; if an increase permits additional sales, Tenon says it will file another prospectus supplement before making them.
Tenon Medical, Inc. reported that Chief Revenue Officer Thomas Henry Batton Jr. received a grant of 10,000 restricted stock units upon his appointment. Each RSU represents a contingent right to receive one common share upon vesting. The award was made under the Tenon Medical, Inc. 2022 Equity Incentive Plan and vests over three years, subject to continued service; it has no expiration date.
Tenon Medical, Inc. (TNON) entered into a warrant inducement transaction with an institutional holder under which the holder agreed to immediately exercise 572,179 existing Series A warrants at an exercise price of $5.02 per share, generating gross cash proceeds of approximately $2.87 million for the company.
In return, Tenon issued new unregistered five-year Series B warrants to purchase up to 858,269 shares of common stock, also at $5.02 per share, equal to 150% of the shares issued upon exercise of the existing warrants. The New Warrants were issued in a private placement relying on Section 4(a)(2) of the Securities Act and are immediately exercisable on issuance.
WallachBeth Capital LLC is serving as financial advisor and will receive a 7% cash fee on aggregate gross proceeds plus up to $65,000 in reimbursed legal expenses. Tenon plans to use the net proceeds for working capital and general corporate purposes and has agreed to file a resale registration statement covering the shares issuable upon exercise of the New Warrants within 30 days, using commercially reasonable efforts to have it declared effective within 60 to 90 days, depending on SEC review.
Tenon Medical, Inc. (TNON) reported that HRT FINANCIAL LP, a ten percent owner, executed multiple open-market transactions in its common stock from September 8–10, 2026. The firm purchased 108,140 shares and sold 125,925 shares, for a net of 17,785 more shares sold than bought.
Reported prices ranged from $2.61 to $5.56 per share, including purchases such as 31,227 shares at $2.92 and sales such as 65,582 shares at $5.56. A footnote states that the transactions with the related note resulted in short sales. No Rule 10b5-1 trading plan is reported.
Tenon Medical, Inc. (TNON) reported that its Chief Financial Officer, Kevin Williamson, had 30 restricted stock units vest and convert into 30 shares of common stock on September 8, 2026, from RSUs granted November 5, 2024 and adjusted for a 1-for-35 reverse stock split effected August 10, 2026. On September 9, 2026, 11 of the resulting common shares were delivered or withheld at a price of $3.45 per share to pay the associated tax liability.
Tenon Medical, Inc. (TNON) reported that it has fully repaid its outstanding original issue discount senior convertible promissory notes, which had an aggregate principal balance of approximately $5.16 million, on September 9, 2026, ahead of their September 11, 2026 maturity date. The Notes were issued on March 11, 2026.
The company states that this early repayment strengthens its balance sheet and removes the potential conversion of the Notes into common stock at a discount to market prices, which would have created dilution. Tenon highlights that eliminating this obligation provides greater financial flexibility to support commercialization of its SI Joint fusion systems and broader growth initiatives.
Tenon Medical, Inc. (TNON) reported that major shareholder HRT FINANCIAL LP, a ten percent owner, both bought and sold Tenon common stock in early September 2026. On September 3, HRT FINANCIAL LP purchased 1,658 shares at $3.98 per share, then on September 4 sold 1,506 shares at $3.70 per share in open market or private transactions. Overall, these reported trades represent a small net purchase of 152 shares, and no post-transaction share balance is stated.
Tenon Medical, Inc. (TNON) has filed a resale prospectus covering up to 1,836,046 shares of common stock, all to be offered from time to time by existing holders. The shares consist mainly of stock underlying pre-funded and Series A warrants from an August 2026 private placement, securities from a November 2025 private placement, shares issued to executives and employees under compensation arrangements, and shares issued or issuable to SiVantage, Inc. in connection with an asset acquisition.
The company is not selling any shares in this offering and will not receive proceeds from resales, but it will receive cash if the November 2025 and August 2026 warrants are exercised, which it currently plans to use for debt repayment, working capital and general corporate purposes. Assuming exercise of all covered warrants and issuance of all SiVantage milestone shares, common stock outstanding would be 2,768,975 shares, compared to 1,032,578 shares outstanding as of August 31, 2026. All share figures reflect a 1‑for‑35 reverse stock split effective August 10, 2026.
Tenon Medical, Inc. (TNON) reports a private exempt offering of securities under Regulation D, claiming the Rule 506(b) exemption. The company indicates a total amount sold of $3,000,000 with $0 remaining to be sold, suggesting the offering has been fully subscribed as reported here.
The offering includes equity, options, warrants or other rights to acquire securities, and the securities issuable upon exercise of those rights. WallachBeth Capital LLC is identified in a sales compensation role, and stated finders’ fees are $0. The notice is signed on behalf of Tenon Medical by Chief Executive Officer and President Steven M. Foster.